OS Therapies Incorporated
$1.42
-2.1%OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.7).
Valuation inputs: P/E -2.7, earnings yield N/A, momentum -2.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -10.9%, ROIC -7.5%).
Profitability stack: net margin 0.0%, ROE -10.9%, ROIC -7.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +85.3%, momentum -2.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
OS Therapies Incorporated Market vs Earnings Trajectory
Loading price and EPS data...
OS Therapies Incorporated Fair Value Envelope
No Revenue Data
OSTX has not reported any revenue values in the available annual periods.
OS Therapies Incorporated Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
OSTX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
OSTX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
OSTX has not reported any net profit margin values in the available annual periods.
OS Therapies Incorporated Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
OS Therapies Incorporated Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Negative working capital but strong cash position suggests an efficient operating model (common in retail/subscription businesses) rather than financial distress.
OS Therapies Incorporated Street Expectations Map
No Target Data
No analyst price targets available for ostx.
OS Therapies Incorporated Insider Positioning
During the last 12 months, there has been no insider trading activity reported for OSTX.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
No Dividend Yield Data
OSTX has not reported any dividend yield values in the available annual periods.
ostx Dividend History
Learning Layer
Related Guides
Build conviction on OSTX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.